<a href="https://www.fiercebiotech.com/biotech/gsks-hepatitis-b-drug-cures-one-fifth-patients-major-step-pervasive-disease" hreflang="en">GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease</a>
GSK's hepatitis B drug, bepirovirsen, has shown promising results in phase 3 trials, achieving a functional cure in nearly 19% of treated patients, significantly higher than existing treatments. The drug, which works by disrupting the virus's life cycle and stimulating the immune response, has potential to reduce long-term complications of chronic hepatitis B, affecting over 240 million people globally.
GSK's bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, has shown promising Phase 3 trial results, achieving a functional cure in 19% of patients, a significant improvement over existing treatments. With the FDA decision expected by October, this development highlights a key opportunity in the biotech sector, particularly in the anti-sense oligo space, and underscores the potential impact of precision medicine approaches in tackling pervasive diseases.